Rezolute (NASDAQ:RZLT) versus Dynavax Technologies (NASDAQ:DVAX) Financial Contrast

Dynavax Technologies (NASDAQ:DVAX) and Rezolute (NASDAQ:RZLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Valuation and Earnings

This table compares Dynavax Technologies and Rezolute’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dynavax Technologies	$232.28 million	5.93	-$6.39 million	$0.06	175.50
Rezolute	N/A	N/A	-$51.79 million	($1.14)	-3.77

Dynavax Technologies has higher revenue and earnings than Rezolute. Rezolute is trading at a lower price-to-earnings ratio than Dynavax Technologies, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Dynavax Technologies and Rezolute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dynavax Technologies	3.91%	1.52%	0.95%
Rezolute	N/A	-60.90%	-54.58%

Analyst Ratings

This is a breakdown of recent ratings and price targets for Dynavax Technologies and Rezolute, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dynavax Technologies	0	1	3	0	2.75
Rezolute	0	0	7	0	3.00

Dynavax Technologies currently has a consensus target price of $25.33, indicating a potential upside of 140.58%. Rezolute has a consensus target price of $10.14, indicating a potential upside of 135.88%. Given Dynavax Technologies’ higher probable upside, equities research analysts clearly believe Dynavax Technologies is more favorable than Rezolute.

Risk & Volatility

Dynavax Technologies has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, Rezolute has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.

Insider and Institutional Ownership

97.0% of Dynavax Technologies shares are held by institutional investors. Comparatively, 83.0% of Rezolute shares are held by institutional investors. 3.0% of Dynavax Technologies shares are held by insiders. Comparatively, 20.8% of Rezolute shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Dynavax Technologies beats Rezolute on 10 of the 13 factors compared between the two stocks.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

About Rezolute

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.